MDWD - MediWound completes enrollment for interim assessment of mid-stage EscharEx study

MediWound (MDWD) completes patient enrollment for the interim assessment of its U.S. EscharEx Phase 2 study for the treatment of venous leg ulcers ((VLUs)).The company said that the interim assessment, meant for futility analysis and potential sample size adjustment, is expected by the end of July 2021.The study, which is targeted to enroll a total of 120 patients by year-end 2021, is designed to assess the safety and efficacy of EscharEx compared to gel vehicle (placebo control) and non-surgical standard-of-care (either enzymatic or autolytic debridement).Shares, which have been down nearly 17% in the last month, were up ~1% post market.

For further details see:

MediWound completes enrollment for interim assessment of mid-stage EscharEx study